A Randomized, Subject- and Investigator-blinded, Placebo-controlled Pharmacodynamic Study of Oral LIK066 in Overweight and Obese Women With Polycystic Ovary Syndrome

Trial Profile

A Randomized, Subject- and Investigator-blinded, Placebo-controlled Pharmacodynamic Study of Oral LIK066 in Overweight and Obese Women With Polycystic Ovary Syndrome

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Jul 2018

At a glance

  • Drugs LIK 066 (Primary)
  • Indications Overweight; Polycystic ovary syndrome
  • Focus Pharmacodynamics
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 09 Jul 2018 Status changed from recruiting to completed.
    • 13 Jun 2018 Planned End Date changed from 18 May 2018 to 25 Jun 2018.
    • 13 Jun 2018 Planned primary completion date changed from 18 May 2018 to 25 Jun 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top